Clinical trialNCT06440005RecruitingPhase 1Interventional

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

SponsorAngiex, Inc.Enrollment80Advanced CancerAngiosarcomaBreast CancerCancerColorectal CancerLiver Cancer+5 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be repeated once every 3, 6 or 9 weeks. Participants may continue study treatment until disease progression, unacceptable toxicity, or consent withdrawal. Subjects will attend an end of treatment visit and will receive two safety follow-up telephone contacts up to 90 days following the last dose of study drug.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Glen Weiss, MD
Medical Lead
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Usc/norris Comprehensive Cancer Center
Los Angeles, California, United States
Diana Hanna, MD
Recruiting
Florida Cancer Specialist
Sarasota, Florida, United States
Judy Wang, MD
Recruiting
Washington University School of Medicine
St Louis, Missouri, United States
Saiama Waqar, MD
Recruiting
Sarah Cannon Research Center
Nashville, Tennessee, United States
Meredith P Pelster, MD
Recruiting
Next Oncology
San Antonio, Texas, United States
Ismael Rodriguez Rivera, MD
Recruiting
Next Oncology
Fairfax, Virginia, United States
Alexander Spira, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

AGX101

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 22 Jul 2024
Primary completion: 6 Sept 2026
Completion: 6 Sept 2027
Last update posted: 11 Feb 2026
Registered enrollment: 80
Registry id: NCT06440005

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.